Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adagio Medical Holdings, Inc.ADGM · Entity 7926 | Director | June 16, 2026 | August 12, 2026 |
| Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617 | Acting Chief Financial Officer | March 02, 2023 | April 04, 2023 |
| CUTERA INCCUTR · Entity 82936 | EVP & Chief Financial Officer | February 12, 2019 | February 14, 2019 |
| Kronos Bio, Inc.KRON · Entity 78257 | Interim CFO | September 15, 2023 | September 18, 2023 |
| Lucira Health, Inc.LHDX · Entity 115613 | Director | June 01, 2022 | June 03, 2022 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Chief Financial Officer | April 17, 2023 | April 26, 2023 |
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | CFO & EVP Admin. and Finance | December 14, 2021 | February 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adagio Medical Holdings, Inc.
Report date June 16, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2036-06-16 | Direct | 30,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 30,000 · Balance 30,000 F1: Annual stock option granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest in equal monthly installments over a one-year period, whereby 1/12th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual stock option granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest in equal monthly installments over a one-year period, whereby 1/12th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026.
Anebulo Pharmaceuticals, Inc.
Report date March 02, 2023 · Filed April 04, 2023
This filing explicitly reported no securities owned.
CUTERA INC
Report date February 12, 2019 · Filed February 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 31,161 |
Reported balance
After 2019-02-12 transaction · row 1
1 source rowRow 1 · 2019-02-12 · Grant · Acquired 18,128 · Balance 31,161 F1: Grant of Restricted Stock Units (RSUs) that will entitle the Reporting Person to receive one share of Common Stock per one RSU. The RSUs vest according to the following schedule: 1/4th annually, commencing from January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock Units (RSUs) that will entitle the Reporting Person to receive one share of Common Stock per one RSU. The RSUs vest according to the following schedule: 1/4th annually, commencing from January 1, 2019.
Kronos Bio, Inc.
Report date September 15, 2023 · Filed September 18, 2023
This filing explicitly reported no securities owned.
Lucira Health, Inc.
Report date June 01, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2032-05-31 | Direct | 59,459 |
Reported balance
After 2022-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 59,459 · Balance 59,459 F1: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting.
NEKTAR THERAPEUTICS
Report date April 17, 2023 · Filed April 26, 2023
This filing explicitly reported no securities owned.
PULSE BIOSCIENCES, INC.
Report date December 14, 2021 · Filed February 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.94 · Expires 2029-11-18 | Direct | 51,922 |
Reported balance
After 2021-12-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-14 · Grant · Acquired 25,961 · Balance 51,922 F1: On November 18, 2019, the reporting person was granted an option to purchase 103,842 shares of the issuer's common stock. The option vests based upon the achievement of performance objectives, with vesting targets no less than 25% vesting per year upon achievement of said objectives established by the Compensation Committee of the issuer, subject to the reporting person's continued service through each vesting date. The performance objectives for 2021 were met, resulting in the vesting of the option as to 25,961 shares. F2: Represents the options which vested on the 2020 vesting date and the options which vested on the 2021 vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 18, 2019, the reporting person was granted an option to purchase 103,842 shares of the issuer's common stock. The option vests based upon the achievement of performance objectives, with vesting targets no less than 25% vesting per year upon achievement of said objectives established by the Compensation Committee of the issuer, subject to the reporting person's continued service through each vesting date. The performance objectives for 2021 were met, resulting in the vesting of the option as to 25,961 shares.
F2: Represents the options which vested on the 2020 vesting date and the options which vested on the 2021 vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Aug 12, 2026 17:40 UTC | Adagio Medical Holdings, Inc. ADGM · Entity 7926 | GrantNon-qualified stock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001218574-26-000002 · form4-08122026_050836.xml · derivative · entry 1 GARDINER SANDRA A. · CIK 0001218574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-16 F1 · security: Annual stock option granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest in equal monthly installments over a one-year period, whereby 1/12th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026. F1 · derivative.exercise_date: Annual stock option granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "Option"). The Option will vest in equal monthly installments over a one-year period, whereby 1/12th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of 06/16/2026. Read SEC document |
| March 20, 2025 Filed Mar 21, 2025 22:59 UTC | Adagio Medical Holdings, Inc. ADGM · Entity 7926 | GrantNon-qualified stock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001415889-25-008805 · form4-03212025_100335.xml · derivative · entry 1 GARDINER SANDRA A. · CIK 0001218574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-07-31 F1 · security: Stock option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Option will vest over a three-year period, whereby 1/36th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of July 31, 2024. F1 · derivative.exercise_date: Stock option granted pursuant to Issuer's 2024 Equity Incentive Plan (the "Option"). Option was approved by the Issuer's Compensation Committee on March 20, 2025. The Option will vest over a three-year period, whereby 1/36th of shares underlying the Option shall vest in equal monthly installments at the conclusion of each month of continuous service after the vesting commencement date of July 31, 2024. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:36 UTC | Lucira Health, Inc. LHDX · Entity 115613 | GrantStock Option (right to buy) · Derivative | 59,459 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001209191-22-034078 · doc4.xml · derivative · entry 1 GARDINER SANDRA A. · CIK 0001218574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,459 Underlying: Common Stock · 59,459 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to this option will vest upon the earlier of the one year anniversary of the grant date of June 1, 2022 or immediately prior to the next annual meeting. Read SEC document |
| December 14, 2021 Filed Feb 28, 2022 18:42 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 25,961 | $0.00 Strike: $13.94 | $0.00 |
DisclosureSEC source: 0000899243-22-008015 · doc4.xml · derivative · entry 1 GARDINER SANDRA A. · CIK 0001218574 · CFO & EVP Admin. and Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,922 Underlying: Common Stock · 25,961 shares Expires 2029-11-18 F1 · derivative.underlying_shares: On November 18, 2019, the reporting person was granted an option to purchase 103,842 shares of the issuer's common stock. The option vests based upon the achievement of performance objectives, with vesting targets no less than 25% vesting per year upon achievement of said objectives established by the Compensation Committee of the issuer, subject to the reporting person's continued service through each vesting date. The performance objectives for 2021 were met, resulting in the vesting of the option as to 25,961 shares. F2 · balance_after: Represents the options which vested on the 2020 vesting date and the options which vested on the 2021 vesting date. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 22:18 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $24.03 | $0.00 |
DisclosureSEC source: 0001209191-21-022928 · doc4.xml · derivative · entry 3 GARDINER SANDRA A. · CIK 0001218574 · CFO & EVP Admin. and Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-03-22 F3 · derivative.exercise_date: The shares subject to the option will vest in equal annual installments over the following four years on the anniversary of March 1, 2021, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 23, 2021 Filed Mar 24, 2021 22:18 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 8,750 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-21-022928 · doc4.xml · derivative · entry 2 GARDINER SANDRA A. · CIK 0001218574 · CFO & EVP Admin. and Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires 2030-05-18 F2 · shares: Represents the acquisition of vested options upon the determination of the Compensation Committee of the Board of Directors of the Issuer that certain performance conditions were met in 2020 with respect to performance-based stock options granted to the Reporting Person on May 18, 2020. F2 · derivative.exercise_date: Represents the acquisition of vested options upon the determination of the Compensation Committee of the Board of Directors of the Issuer that certain performance conditions were met in 2020 with respect to performance-based stock options granted to the Reporting Person on May 18, 2020. Read SEC document |
| December 09, 2020 Filed Mar 24, 2021 22:18 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 25,961 | $0.00 Strike: $13.94 | $0.00 |
DisclosureSEC source: 0001209191-21-022928 · doc4.xml · derivative · entry 1 GARDINER SANDRA A. · CIK 0001218574 · CFO & EVP Admin. and Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,961 Underlying: Common Stock · 25,961 shares Expires 2029-11-18 F1 · shares: Represents the acquisition of vested options upon the determination of the Compensation Committee of the Board of Directors of the Issuer that certain performance conditions were met with respect to performance-based stock options granted to the Reporting Person on November 18, 2019. F1 · derivative.exercise_date: Represents the acquisition of vested options upon the determination of the Compensation Committee of the Board of Directors of the Issuer that certain performance conditions were met with respect to performance-based stock options granted to the Reporting Person on November 18, 2019. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:15 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 103,842 | $0.00 Strike: $13.94 | $0.00 |
DisclosureSEC source: 0001209191-19-057143 · doc4.xml · derivative · entry 2 GARDINER SANDRA A. · CIK 0001218574 · CFO & EVP Admin. and Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,842 Underlying: Common Stock · 103,842 shares Expires 2029-11-18 F2 · derivative.exercise_date: The shares subject to the option shall vest based upon the achievement of performance objectives, with vesting targets set no less than one-fourth (1/4) vesting per year upon achievement of said objectives established by the Compensation Committee of the Issuer, subject to the Reporting Person's continued service through each vesting date. If performance objectives are not set by the Compensation Committee, the shares subject to the option will vest in equal annual installments over the following four years on the anniversary of the grant date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:15 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 103,842 | $0.00 Strike: $13.94 | $0.00 |
DisclosureSEC source: 0001209191-19-057143 · doc4.xml · derivative · entry 1 GARDINER SANDRA A. · CIK 0001218574 · CFO & EVP Admin. and Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,842 Underlying: Common Stock · 103,842 shares Expires 2029-11-18 F1 · derivative.exercise_date: The shares subject to the option will vest in equal annual installments over the following four years on the anniversary of the grant date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 16:32 UTC | CUTERA INC CUTR · Entity 82936 | GrantCOMMON STOCK | 18,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-002643 · rdgdoc.xml · nonDerivative · entry 1 GARDINER SANDRA A. · CIK 0001218574 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,161 F1 · shares: Grant of Restricted Stock Units (RSUs) that will entitle the Reporting Person to receive one share of Common Stock per one RSU. The RSUs vest according to the following schedule: 1/4th annually, commencing from January 1, 2019. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 18:20 UTC | CUTERA INC CUTR · Entity 82936 | Tax withholdingCOMMON STOCK | 559 | $17.02 | $9,514.18 |
DisclosureSEC source: 0001437749-19-000261 · rdgdoc.xml · nonDerivative · entry 3 GARDINER SANDRA A. · CIK 0001218574 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,033 F3 · shares: Represents the total number of shares withheld by the Company to settle the Reporting Person's minimum tax liability for 1,368 Restricted Stock Units (RSUs) vesting on January 1, 2019. Such withholding is required by the Company's Amended 2004 Equity Incentive Plan. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 18:20 UTC | CUTERA INC CUTR · Entity 82936 | Tax withholdingCOMMON STOCK | 1,117 | $17.02 | $19,011.34 |
DisclosureSEC source: 0001437749-19-000261 · rdgdoc.xml · nonDerivative · entry 2 GARDINER SANDRA A. · CIK 0001218574 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,592 F2 · shares: Represents the total number of shares withheld by the Company to settle the Reporting Person's minimum tax liability for 2,734 Performance Stock Units (PSUs) vesting on January 1, 2019. Such withholding is required by the Company's Amended 2004 Equity Incentive Plan. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 18:20 UTC | CUTERA INC CUTR · Entity 82936 | GrantCOMMON STOCK | 2,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-000261 · rdgdoc.xml · nonDerivative · entry 1 GARDINER SANDRA A. · CIK 0001218574 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,709 F1 · shares: Stock issued pursuant to the vesting of Performance Share Units (PSU's) granted on February 13, 2018 Read SEC document |
| December 15, 2018 Filed Dec 17, 2018 18:31 UTC | CUTERA INC CUTR · Entity 82936 | Tax withholdingCOMMON STOCK | 704 | $16.52 | $11,630.08 |
DisclosureSEC source: 0001437749-18-022139 · rdgdoc.xml · nonDerivative · entry 1 GARDINER SANDRA A. · CIK 0001218574 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,975 F1 · shares: Represents the total number of shares withheld by the Company to settle the Reporting Person's minimum tax liability for 2,036 Restricted Stock Units (RSUs) vesting on December 15, 2018. Such withholding is required by the Company's Amended 2004 Equity Incentive Plan. Read SEC document |
| December 01, 2018 Filed Dec 4, 2018 16:32 UTC | CUTERA INC CUTR · Entity 82936 | Tax withholdingCOMMON STOCK | 442 | $20.50 | $9,061.00 |
DisclosureSEC source: 0001437749-18-021571 · rdgdoc.xml · nonDerivative · entry 1 GARDINER SANDRA A. · CIK 0001218574 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,679 F1 · shares: Represents the total number of shares withheld by the Company to settle the Reporting Person's minimum tax liability for 1,281 Restricted Stock Units (RSUs) vesting on December 1, 2018. Such withholding is required by the Company's Amended 2004 Equity Incentive Plan. F2 · balance_after: The amount of securities beneficially owned includes 495 shares acquired on November 1, 2018 by the Reporting Person in an exempt transaction under the Issuer's Amended 2004 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 19:26 UTC | CUTERA INC CUTR · Entity 82936 | GrantCOMMON | 5,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-002714 · rdgdoc.xml · nonDerivative · entry 1 GARDINER SANDRA · CIK 0001218574 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,626 F1 · shares: Grant of Restricted Stock Units (RSUs) that will entitle the Reporting Person to receive one share of Common Stock per one RSU. The RSUs vest according to the following schedule: 1/4th annually, commencing from January 1, 2019. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 18:27 UTC | CUTERA INC CUTR · Entity 82936 | GrantStock Option (Right to Buy) · Derivative | 16,005 | $0.00 Strike: $47.40 | $0.00 |
DisclosureSEC source: 0001437749-17-020915 · rdgdoc.xml · derivative · entry 3 GARDINER SANDRA · CIK 0001218574 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,005 Underlying: Common Stock · 16,005 shares Expires 2024-12-15 F3 · derivative.exercise_date: Options vest according to the following schedule: 1/4th of the shares shall vest on 12/1/2018 and 1/48th monthly thereafter. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 18:27 UTC | CUTERA INC CUTR · Entity 82936 | GrantCOMMON | 2,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-020915 · rdgdoc.xml · nonDerivative · entry 2 GARDINER SANDRA · CIK 0001218574 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,157 F2 · shares: Grant of RSUs that will entitle the Reporting Person to receive one share of Common Stock per one RSU. 100% of these RSUs will vest on December 15, 2018. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 18:27 UTC | CUTERA INC CUTR · Entity 82936 | GrantCOMMON | 5,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-020915 · rdgdoc.xml · nonDerivative · entry 1 GARDINER SANDRA · CIK 0001218574 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,121 F1 · shares: Grant of Restricted Stock Units (RSUs) that will entitle the Reporting Person to receive one share of Common Stock per one RSU. These RSUs vest over four years at the rate of 25% annually on December 1, 2018 to December 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.